HIV Mutation Detail Information

> Y181I Search Result

Mutation Information

Mutation Site	Y181I
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Relevant Drug	bictegravir (BIC);emtricitabine (FTC);tenofovir alafenamide;rilpivirine (RPV)
Country	Australia;Europe;North America

Literature Information

PubMed PMID	31430369
Disease	HIV infection/AIDS
Published Year	2019
Journal	The Journal of antimicrobial chemotherapy
Title	Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Author	Andreatta K,Willkom M,Martin R,Chang S,Wei L,Liu H,Liu YP,Graham H,Quirk E,Martin H,White KL
Evidence	Table3;NNRTI-R substitutions were observed in 23% (124/543) of participants; the most frequently detected substitutions were K103N/S in 12% (64/543) and rilpivirine-associated resistance substitutions (L100I, K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C or M320I/L) in 10% (53/543) (Table 3).

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation